Additional file 7: **Table S2**  Overview of pembrolizumab immunogenicity findings in KEYNOTE-054 (ClinicalTrials.gov Identifier, NCT02362594)

|  |  |
| --- | --- |
| **Pembrolizumab in the adjuvant setting: melanoma** | |
|  | **Treatment** |
| Immunogenicity status | 200 mg Q3W |
| Assessable patientsa | 496 |
| Inconclusive patientsb | 1 |
| Evaluable patientsc | 495 |
| Negatived | 473 (95.6%) |
| Non–treatment-emergent positived | 5 (1.0%) |
| Neutralizing negative | 5 (1.0%) |
| Neutralizing positive | 0 |
| Treatment-emergent positived | 17 (3.4%) |
| Neutralizing negative | 17 (3.4%) |
| Neutralizing positive | 0 |

aIncluded are patients with at least 1 ADA sample available after treatment with pembrolizumab.

bInconclusive patients are the number of patients with no positive ADA samples present and the drug concentration in the last sample above the DTL.

cEvaluable patients are the total number of negative and positive patients (non–treatment emergent and treatment emergent).

dDenominator was total number of evaluable patients.

ADA, antidrug antibody; DTL, drug tolerance limit; Q3W, every 3 weeks.